Evidence map›Paper›PMID 41368357›Full record

ArticleFrontiers in neurology2025

Impact of PCSK9 inhibitor on T lymphocyte subsets and cytokines in patients with acute ischemic stroke: an exploratory analysis of a randomized clinical trial.

Jiahui Liu, Chao Han, Xiaofei Ji, Hua Cao, Shuna Chen, Chengcheng Tan, Xinqing Hao, Yuki Joyama, Wei Zou, Ying Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiahui Liu *Stem Cell Clinical Research Center, National Joint Engineering Laboratory, Regenerative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Chao Han *Stem Cell Clinical Research Center, National Joint Engineering Laboratory, Regenerative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Xiaofei JiDepartment of Neurology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Hua CaoDepartment of Neurology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Shuna ChenStem Cell Clinical Research Center, National Joint Engineering Laboratory, Regenerative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Chengcheng TanStem Cell Clinical Research Center, National Joint Engineering Laboratory, Regenerative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Xinqing HaoStem Cell Clinical Research Center, National Joint Engineering Laboratory, Regenerative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Yuki JoyamaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan.
Wei ZouStem Cell Clinical Research Center, National Joint Engineering Laboratory, Regenerative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Ying LiStem Cell Clinical Research Center, National Joint Engineering Laboratory, Regenerative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Jing LiuStem Cell Clinical Research Center, National Joint Engineering Laboratory, Regenerative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: PCSK9 inhibitors are lipid-lowering agents with pleiotropic properties including immune-inflammatory modulation. However, the effects of PCSK9 inhibitors on the peripheral immune profile of patients with acute ischemic stroke (AIS) remain unknown. In this analysis, we aim to further investigate the impact of PCSK9 inhibitor evolocumab on clinical outcomes, immune responses, and cytokines in AIS patients. Methods: In this study, a total of 100 patients with AIS were included for the current analysis ( Results: Compared with the AT group, patients in the PI group had a significantly lower incidence of early neurological deterioration (END) ( Conclusions: This study demonstrated that adjunctive evolocumab therapy significantly improved clinical outcomes and inhibited the elevation of the plasma IL-6 compared to atorvastatin monotherapy in AIS patients, whereas peripheral blood T lymphocyte subsets did not change in this trial. Trial registration: http://www.chictr.org.cn; Identifier: ChicTR2200059445. Date of registration: 29 April 2022.

Indexed as

acute ischemic strokecytokinesearly neurological deteriorationevolocumabPCSK9 inhibitorsT cell compartmentsT lymphocyte subsets

Identifiers

PMID41368357
PMCPMC12682626

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.